A STUDY ON COAGULATION PROFILE OF COVID POSITIVE PATIENTS WITH CT CHANGES

Abstract

More than 25.3 million people have been impacted by the current pandemic since COVID-19 (coronavirus disease) had been first noticed in Wuhan, China in 2019. Individuals who are at elevated risk as well as show more than one manifestation in addition to pulmonary complications have a high death rate [1-3]. In individuals with COVID-19, coagulation abnormalities are commonly observed and are linked to a poorer prognosis and survival rate. Elevated D-dimer levels had been consistently correlated with worse results as well as mortality. Prothrombin time (P.T.) extension has also been observed under extreme circumstances, along with it occurring in non-survivors more commonly. Phenol levels can rise to their maximum limits during the acute reaction to the infection and remain there as the disease progresses; however, in a group of patients suffering from coronavirus pneumonia, before death, there has been a noted reduction in these levels [4]. Hematological abnormalities in patients suffering from COVID 19 point to a procoagulant state associated with venous and arterial thrombosis, which was more commonly noted in situations of severe cases [5-6]. VTEs (Venous thromboembolic events) happened in 2.9percent of 138 COVID-19 patients, according to a Chinese study. Nonetheless, in a small group of really ill patients admitted to the ICU, the VTE rate had been 20percent. When the pulmonary embolism rates in a single centre in France had been contrasted among general patients of ICU from the prior year and ICU admissions due to COVID-19 in 2020, the results showed rates of 20.6% and 6.1%, respectively. Up to 50percent of patients with severe COVID-19 symptoms have been documented to have coagulopathy, and over 70percent of cases have been found to have disseminated intravascular coagulopathy. Because prophylactic therapy appears to lower mortality from coagulation abnormalities, it has been recommended for hospitalized patients.